Tagged with CIS

Janssen In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision treatments. Sterkens also highlights how Janssen is positioning itself in the emerging markets under his remit and how the ongoing…

China Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the core of the company; the innovation behind their flagship product, a subcutaneous injection PD-L1 antibody that is also stable at…

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Korea Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu assesses the changing environment for clinical research in Korea and offers her view on the successes and scope for improvement…

BIOTECH This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the UK as the NHS begins to offer gene therapies tailored to individual patients. Hospitals across England have connected to specialist…

Spain Miguel Angel Calleja, president of the Spanish Society of Hospital Pharmacists (SEFH) introduces the society and the important role it plays in Spain’s healthcare system as the perfect partner for the new government. Furthermore, he highlights the strides they are taking to implement new digital technologies into hospital pharmacies across…

China Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could you briefly introduce your company, Considerin Group, to our international audience? “We are the only Chinese company to have our…

Ukraine Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of…

Switzerland “Get it done! That is what CARBOGEN AMCIS is all about!” – The CEO of the Swiss drug development and commercialization services company elaborates on the company’s strong mindset and declares customer intimacy to be their unique selling point. CARBOGEN AMCIS celebrated its 10th year since joining the Dishman group.…

Pharma Juan Fransisco Millán Sobaranes of Cetifarma, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discussed the agency’s major milestones and its main priorities for ensuring transparency, notably with regards to patient groups, healthcare practitioners, and clinical trials.   You were part of the initial team…

Pharma  Country manager AbdelAziz Shaheen discusses Pfizer’s current and recent investments in Egypt, which include significant contributions to the continuous education of Egyptian pharmacists and health care professionals. With 54 years history in Egypt, expanding manufacturing operations, and ambitions to see Egypt to become a production hub for Africa, Pfizer Egypt is…

pharma Francisco García was appointed as the executive director for the Puerto Rico Manufacturers Association (PRMA) in August 2015. He stresses the importance of developing Puerto Rico’s entrepreneurial talent and startup clusters as his main initiatives. As you have recently taken over as executive director of PRMA, could you outline the…